Eupraxia Pharmaceuticals Ratios and Metrics

Market cap in millions CAD. Fiscal year is January - December.

Millions CAD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2017 - 2019
Period Ending	May '25 May 12, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2017 - 2019
Market Capitalization	191	161	147	79	35	-	Upgrade
Market Cap Growth	11.29%	9.66%	85.89%	125.87%	-	-	Upgrade
Enterprise Value	195	147	127	58	10	-	Upgrade
Last Close Price	5.33	4.51	5.37	3.65	2.45	-	Upgrade
PB Ratio	4.92	3.51	124.32	8.08	1.83	-	Upgrade
P/TBV Ratio	-	65.70	50.06	7.48	1.75	-	Upgrade
Debt / Equity Ratio	0.00	0.00	11.71	1.25	0.52	-0.59	Upgrade
Quick Ratio	12.59	10.74	1.01	6.00	13.38	0.03	Upgrade
Current Ratio	13.00	11.10	1.02	6.08	13.49	0.05	Upgrade
Return on Equity (ROE)	-116.77%	-157.31%	-715.19%	-178.04%	-	-	Upgrade
Return on Assets (ROA)	-52.06%	-61.14%	-88.37%	-52.20%	-68.51%	-59.25%	Upgrade
Return on Capital (ROIC)	-62.63%	-78.03%	-126.40%	-58.41%	-110.75%	-	Upgrade
Earnings Yield	-20.05%	-22.84%	-25.44%	-31.75%	-68.66%	-	Upgrade
FCF Yield	-22.66%	-26.96%	-18.77%	-25.12%	-43.73%	-	Upgrade
Buyback Yield / Dilution	-37.52%	-40.52%	-25.21%	-55.45%	-102.75%	-0.01%	Upgrade

Updated Mar 20, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.